Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy

被引:0
|
作者
Hartrampf, Philipp E. [1 ]
Mihatsch, Patrick W. [2 ]
Seitz, Anna Katharina [3 ]
Solnes, Lilja B. [4 ]
Rowe, Steven P. [4 ]
Pomper, Martin G. [4 ]
Kuebler, Hubert [3 ]
Bley, Thorsten A. [2 ]
Buck, Andreas K. [1 ]
Werner, Rudolf A. [1 ,4 ]
机构
[1] Univ Hosp Wurzburg, Dept Nucl Med, Wurzburg, Germany
[2] Univ Hosp Wurzburg, Dept Diagnost & Intervent Radiol, Wurzburg, Germany
[3] Univ Hosp Wurzburg, Dept Urol & Paediat Urol, Wurzburg, Germany
[4] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD USA
关键词
PSMA; prostate cancer; radioligand therapy; overall survival; body composition; ANDROGEN-DEPRIVATION THERAPY; CLINICAL-OUTCOMES; OPEN-LABEL; MEN; FAT; CHEMOTHERAPY; MITOXANTRONE; CABAZITAXEL; ABIRATERONE; PREDNISONE;
D O I
10.2967/jnumed.122.265379
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In patients with prostate cancer scheduled for systemic treatment, being overweight is linked to prolonged overall survival (OS), whereas sarcopenia is associated with shorter OS. We investigated fat-related and body composition parameters in patients undergoing prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) to assess their predictive value for OS. Methods: Body mass index (BMI, in kg/m(2)) and CT-derived body composition parameters (total, subcutaneous, visceral fat area, and psoas muscle area at the L3-L4 level) were determined for 171 patients scheduled for PSMA-directed RLT. After normalization for stature, the psoas muscle index was used to define sarcopenia. Outcome analysis was performed using Kaplan-Meier curves and Cox regression including fat-related and other clinical parameters (Gleason score, C-reactive protein [CRP], lactate dehydrogenase [LDH], hemoglobin, and prostate-specific antigen levels). The Harrell C-index was used for goodness-of-fit analysis. Results: Sixty-five patients (38%) had sarcopenia, and 98 patients (57.3%) had increased BMI. Relative to the 8-mo OS in normal-weight men (BMI < 25), overweight men (25 = BMI > 30) and obese men (BMI =30) achieved a longer OS of 14 mo (hazard ratio [HR], 0.63; 95% CI, 0.40-0.99; P = 0.03) and 13 mo (HR, 0.47; 95% CI, 0.29-0.77; P = 0.004), respectively. Sarcopenia showed no impact on OS (11 vs. 12 mo; HR, 1.4; 95% CI, 0.91-2.1; P = 0.09). Most of the body composition parameters were tightly linked to OS on univari-able analyses, with the highest C-index for BMI. In multivariable analy-sis, a higher BMI (HR, 0.91; 95% CI, 0.86-0.97; P = 0.006), lower CRP (HR, 1.09; 95% CI, 1.03-1.14; P < 0.001), lower LDH (HR, 1.08; 95% CI, 1.03-1.14; P < 0.001), and longer interval between initial diagnosis and RLT (HR, 0.95; 95% CI, 0.91-0.99; P = 0.02) were significant pre-dictors of OS. Conclusion: Increased fat reserves assessed by BMI, CRP, LDH, and interval between initial diagnosis and RLT, but not CT-derived body composition parameters, were relevant predictors for OS. As BMI can be altered, future research should investigate whether a high-calorie diet before or during PSMA RLT may improve OS.
引用
收藏
页码:1272 / 1278
页数:7
相关论文
共 50 条
  • [1] Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
    Teo, Min Yuen
    Morris, Michael J.
    CANCER JOURNAL, 2016, 22 (05): : 347 - 352
  • [2] Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
    Lunger, Lukas
    Tauber, Robert
    Feuerecker, Benedikt
    Gschwend, Jurgen E.
    Eiber, Matthias
    Heck, Matthias M.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (10) : 3963 - 3971
  • [3] Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
    Vlachostergios, Panagiotis J.
    Niaz, Muhammad Junaid
    Sun, Michael
    Mosallaie, Seyed Ali
    Thomas, Charlene
    Christos, Paul J.
    Osborne, Joseph R.
    Molina, Ana M.
    Nanus, David M.
    Bander, Neil H.
    Tagawa, Scott T.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
    Chen, Jiaxian
    Qi, Lin
    Tang, Yongxiang
    Tang, Guyu
    Gan, Yu
    Cai, Yi
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [5] Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
    Hartrampf, Philipp E.
    Weinzierl, Franz-Xaver
    Seitz, Anna Katharina
    Kuebler, Hubert
    Essler, Markus
    Buck, Andreas K.
    Werner, Rudolf A.
    Bundschuh, Ralph A.
    PROSTATE, 2022, 82 (14): : 1406 - 1412
  • [6] 177Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer
    Parihar, Ashwin Singh
    Hofman, Michael S.
    Iravani, Amir
    RADIOLOGY, 2023, 306 (02)
  • [7] Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy
    Lu, Hsi-Huei
    Chiu, Nan-Tsing
    Tsai, Mu-Hung
    ANNALS OF NUCLEAR MEDICINE, 2024, 38 (07) : 508 - 515
  • [8] 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
    Baum, Richard P.
    Kulkarni, Harshad R.
    Schuchardt, Christiane
    Singh, Aviral
    Wirtz, Martina
    Wiessalla, Stefan
    Schottelius, Margret
    Mueller, Dirk
    Klette, Ingo
    Wester, Hans-Juergen
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) : 1006 - 1013
  • [9] The role of prostate-specific antigen changes in predicting overall survival after progressive-site directed therapy for oligoprogressive castration-resistant prostate cancer
    Yoshida, Soichiro
    Takahara, Taro
    Tanaka, Hajime
    Yokoyama, Minato
    Yoshimura, Ryoichi
    Fujii, Yasuhisa
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (07) : 616 - 617
  • [10] Prostate-specific membrane antigen radioligand therapy of prostate cancer
    Beheshti, Mohsen
    Heinzel, Alexander
    von Mallek, Dirk
    Filss, Christian
    Mottaghy, Felix M.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (01): : 29 - 36